Introduction
============

Parasympathetic neurogenesis is a morphologic phenomenon of the tumor microenvironment that presents as distribution of parasympathetic nerves in the tumor stroma ([@b1]). Moreover, parasympathetic neurogenesis is associated with progression of invasion and metastasis in prostate cancer ([@b1]). Although neurogenesis is generally considered as a poor risk factor for tumor prognosis ([@b2], [@b3], [@b4], [@b5]), the phenomenon of parasympathetic neurogenesis in pancreatic ductal adenocarcinoma (PDAC) has not been studied.

Tumor budding reflects a type of diffusely infiltrative growth frequently observed in gastrointestinal carcinomas and is defined as the presence of detached isolated single cells or small cell clusters (up to five cells) scattered in the stroma at the invasive tumor front ([@b6], [@b7], [@b8], [@b9], [@b10], [@b11]). Tumor budding has been suggested to reflect the process of epithelial-mesenchymal transition ([@b12]). In a previous study, it showed that tumor budding occurs frequently in pancreatic cancer and may be used as a parameter of tumor aggressiveness and an indicator of unfavorable outcomes ([@b13]). In following years, our results were further confirmed in other studies ([@b14], [@b15], [@b16]).

Based on previous findings in prostate cancer ([@b1]), we hypothesized that parasympathetic neurogenesis may be associated with the frequent occurrence of tumor budding in PDAC and may play a role in PDAC invasion and metastasis. We therefore analyzed parasympathetic neurogenesis at the invasive front of the tumor in 59 PDAC patients with available information on clinicopathologic data, follow-up, and adjuvant therapy. Parasympathetic neurogenesis was correlated with clinicopathologic data, especially the presence of tumor budding and prognosis.

Methods
=======

 *Patients and tissue samples*
==============================

With the approval of the Institutional Review Board, the data of 76 consecutive patients who were treated with intended radical pancreaticoduodenectomy at the Department of General Surgery, Peking University Third Hospital between 2005 and 2010 were retrospectively reviewed. After excluding patients who did not have a diagnosis of PDAC, 59 patients (77.6%) with PDAC who had available pathologic specimens and 3 specimens of normal pancreatic tissues were enrolled in this study.

The clinicopathologic characteristics and the outcomes of these patients were recorded. The observation period was from February 2005 to December 2014, with a median follow-up time of 15 months (range, 3-84 months). Clinical and pathologic factors, including demographic information, clinical stage, and presence of vessel invasion and neural invasion, were evaluated. The clinical stages of all patients were classified according to the 2009 TNM staging of the International Union against Cancer.

 *Immunohistochemistry*
=======================

Paraffin-embedded PDAC sections (4 μm) were deparaffinized with xylene and rehydrated. Antigen retrieval was performed by heating in an autoclave in 10 mmol/L sodium citrate buffer (pH 6.0). The sections were treated with 3% hydrogen peroxide in methanol to quench the endogenous peroxidase activity and with 1% bovine serum albumin to block non-specific binding, followed by incubation with a rabbit polyclonal antibody against vesicular acetylcholine transporter (VAChT) (1:100, ab-68984; Abcam, CA, USA) overnight at 4 °C. After washing with phosphate-buffered saline (PBS), the sections were incubated with a biotinylated secondary antibody followed by incubation with the streptavidin-horseradish peroxidase complex. The sections were then immersed in 3,3'-diaminobenzidine for 6 min, counterstained with 10% Mayer's hematoxylin, dehydrated, and mounted in crystal mount. PBS was used instead of a primary antibody for the negative control. To minimize variation in immunopositivity, all sections were stained in 3,3'-diaminobenzidine for the same amount of time. One pathologist, who was blinded to the clinical outcome, independently scored the results of the staining.

 *Evaluation of immunohistochemistry and tumor budding*
=======================================================

Parasympathetic neurogenesis was defined as a morphologic phenomenon in the tumor microenvironment, presenting as the distribution of parasympathetic nerves in the tumor stroma (*[Figure 1](#F1){ref-type="fig"}*). For the VAChT-stained tissue sections, a pathologist first selected the area with the highest density of nerve fibers at a low magnification (5×), which was defined as the hotspot field. Subsequently, the number of nerve fibers was counted using 20× magnification (surface 0.785 mm^2^) in high-power fields (200×) and scoring was performed based on the number of nerve fibers in five hotspot fields at 200× magnification.

![Representative photomicrographs (200×) showing staining of parasympathetic nerves by expression of vesicular acetylcholine transporter (VAChT) in normal pancreatic tissue (A), and in pancreatic ductal adenocarcinoma (PDAC) (B). Scattered abnormal nerve fibers were seen in the stroma of PDAC.](cjcr-28-02-180-g001){#F1}

Tumor budding was defined as detached single cells or clusters of fewer than five cells. Cases were evaluated for tumor budding as described in our previous study ([@b6]).

 *Follow-up and statistical analysis*
=====================================

Patients were followed up clinically with physical examinations and abdominal-pelvic computed tomography (CT) performed every 3-6 months. Patients with stage II or III disease received adjuvant chemotherapy depending on their preference. Overall survival (OS) was defined as the time from the first surgery to the date of death (all-cause mortality). Disease-free survival (DFS) was defined as the time from the first surgery to the date of the first evidence of recurrence (local, regional, or metastatic). Follow-up time was defined as the time from the first surgery to the date of the last follow-up. Follow-up information was obtained from office charts, hospital records, and telephone interviews. Follow-up and survival times were recorded in months.

Study data were collected on standard forms, checked for completeness, and double keyed into an Epidata 3.1 database. Continuous variables that did not meet the normal distribution were expressed as median (P25, P75), and the Mann--Whitney U test was used to analyze differences between groups. Categorical variables were described by frequencies and proportions and tested by the Chi-square test or Fisher's exact test. The cut-off value of parasympathetic nerve fibers was determined by receiver operating characteristic (ROC) curves. The Kaplan--Meier method was used to represent survival curves and the log-rank test was used to test significant differences in survival time. Multivariate Cox regression models (Backward Stepwise Likelihood Ratio) were used to analyze factors influencing survival and reported with a hazard ratio (HR) of 1.0 as baseline and 95% confidence interval (95% CI). All analyses were carried out using SPSS 21.0 software (SPSS Inc., Chicago, IL, USA). A two-sided P value of \<0.05 was considered statistically significant in all analyses.

Results
=======

 *Patient demographics*
=======================

The study cohort of 59 patients with resected PDAC had a median age of 63 years (range: 23-77 years). There was a slight male predominance 1.4:1 (male, n=34). The majority of tumors were histological grade Ⅱ \[32 (48%)\] or grade Ⅲ \[21 (31%)\]. Thirty-nine (58%) of the tumors were pT3 and 29 patients (43%) had lymph node metastases. Thirty (50.8%) patients were treated with adjuvant chemotherapy. Twenty-six patients showed recurrence within 6 months, of whom 6 cases had local recurrence, 12 had liver metastasis, 1 had pulmonary metastasis, 1 had abdominal wall metastasis, and 6 had multiple organ metastasis. All of these patients formed the early recurrence group. The observation period was from February 2005 to December 2014, with a median follow-up time of 15 months (range, 3-84 months).

 *Frequency of parasympathetic neurogenesis and association of parasympathetic neurogenesis with clinicopathologic parameters*
==============================================================================================================================

VAChT-positive parasympathetic nerve fibers were not seen in the stroma of 3 cases of normal pancreatic tissues whereas they were presented in all cases of PDAC \[median 18 fibers/(5×0.785) mm^2^, range 4-38 fibers/(5×0.785) mm^2^\] (*[Figure 1](#F1){ref-type="fig"}*).

The diagnostic potential of parasympathetic neurogenesis for predicting death within 2 years is shown in *[Figure 2](#F2){ref-type="fig"}*. In general, parasympathetic neurogenesis was found to be a significant indicator for distinguishing patients who died within 2 years from survivors (area under the ROC curve=0.815, 95% CI: 0.701-0.929, P=0.000). We chose the cut-off value when the Youden's index was the biggest. The ROC curve showed an optimal cut-off value of 15 fibers/(5×0.785) mm^2^ for parasympathetic neurogenesis with 84% sensitivity and 67% specificity (*[Figure 2](#F2){ref-type="fig"}*). Therefore, we divided the cohort into two groups according to the number of parasympathetic neurogenesis: a low-grade parasympathetic neurogenesis group \[parasympathetic neurogenesis ≤15 fibers/(5×0.785) mm^2^\] and a high-grade parasympathetic neurogenesis group \[parasympathetic neurogenesis \>15 fibers/(5×0.785) mm^2^\]. The high-grade parasympathetic neurogenesis group represented 66.1% of cases (39/59).

![ROC curve for parasympathetic neurogenesis as a predictor of death within 2 years.](cjcr-28-02-180-g002){#F2}

The presence of high-grade parasympathetic neurogenesis was associated with a high tumor budding number (P=0.001) and early recurrence (P=0.035). Parasympathetic neurogenesis was not found to be associated with pT stage (P=0.174), N stage (P=0.314), American Joint Committee on Cancer (AJCC) stage (P=0.586), vessel invasion (P=0.626), neural invasion (P=0.233), or histological grade (P=0.522). A complete summary of clinicopathologic associations with parasympathetic neurogenesis is provided in *[Table 1](#T1){ref-type="table"}*.

###### 

Clinicopathologic characteristics in different parasympathetic neurogenesis groups

  Characteristics     Low-grade parasympathetic neurogenesis (N=20)   High-grade parasympathetic neurogenesis (N=39)   P\*
  ------------------- ----------------------------------------------- ------------------------------------------------ -------
  Age, year           64.0 (61.3, 71.0)                               61.0 (54.0, 68.0)                                0.075
  Male                11 (55.0)                                       23 (59.0)                                        0.770
  T stage                                                                                                              0.174
  1-2                 8 (40.0)                                        9 (23.1)                                         
  3-4                 12 (60.0)                                       30 (76.9)                                        
  N stage=1           8 (40.0)                                        21 (53.8)                                        0.314
  AJCC                                                                                                                 0.586
  1                   5 (25.0)                                        6 (15.4)                                         
  2-3                 15 (75.0)                                       33 (84.6)                                        
  R-status positive   1 (5.0)                                         4 (10.3)                                         0.847
  Vessel invasion     6 (30.0)                                        8 (20.5)                                         0.626
  Neural invasion     8 (40.0)                                        22 (56.4)                                        0.233
  G grade                                                                                                              0.522
  1                   3 (15.0)                                        3 (7.7)                                          
  2                   9 (45.0)                                        23 (59.0)                                        
  3                   8 (40.0)                                        13 (33.3)                                        
  Chemotherapy        9 (45.0)                                        21 (53.9)                                        0.520
  Tumor budding       12.5 (6.0, 22.5)                                24.0 (16.0, 41.0)                                0.001
  Early recurrence    5 (25.0)                                        21 (53.8)                                        0.035

 *Prognostic significance of parasympathetic neurogenesis*
==========================================================

Median DFS was 10 and 30 months in patients with high-grade and low-grade parasympathetic neurogenesis, respectively. Univariable OS analysis showed that T stage (log-rank test, P=0.004), N stage (log-rank test, P=0.005), AJCC stage (log-rank test, P=0.001), neural invasion (log-rank test, P=0.048), G stage (log-rank test, P=0.026), chemotherapy (log-rank test, P=0.008), tumor budding (log-rank test, P\<0.001), and the presence of parasympathetic neurogenesis (log-rank test, P\<0.001) were associated with an inferior prognosis (*[Table 2](#T2){ref-type="table"}*, *[Figure 3](#F3){ref-type="fig"}*).

###### 

Univariate Kaplan--Meier survival analysis in PDAC patients under radical resection

  Factors                        Survival time (month)   P\*       
  ------------------------------ ----------------------- --------- ---------
  Gender                                                           0.760
  Female                         13.0                    4.16      
  Male                           17.0                    5.83      
  T stage                                                          0.004
  1-2                            30.0                    8.23      
  3-4                            11.0                    2.02      
  N stage                                                          0.005
  0                              22.0                    4.93      
  1                              10.0                    0.89      
  AJCC                                                             0.001
  1                              38.0                    15.41     
  2-3                            11.0                    2.16      
  R status                                                         0.268
  Negative                       14.0                    3.67      
  Positive                       15.0                    6.57      
  Vessel invasion                                                  0.308
  Negative                       15.0                    3.83      
  Positive                       14.0                    10.29     
  Neural invasion                                                  0.048
  Negative                       22.0                    4.48      
  Positive                       11.0                    2.19      
  G stage                                                          0.026
  1                              58.0                    23.27     
  2                              11.0                    2.26      
  3                              15.0                    4.58      
  Chemotherapy                                                     0.008
  No                             23.0                    6.28      
  Yes                            10.0                    1.83      
  Tumor budding                                                    \<0.001
  ≤17                            26.0                    5.29      
  \>17                           10.0                    1.02      
  Parasympathetic neurogenesis                           \<0.001   
  ≤15                            30.0                    5.55      
  \>15                           10.0                    0.89      

![Kaplan--Meier survival curves for the low-grade parasympathetic neurogenesis group and high-grade parasympathetic neurogenesis group among pancreatic ductal adenocarcinoma patients undergoing radical resection.](cjcr-28-02-180-g003){#F3}

The multivariate Cox regression model using Backward Stepwise (likelihood ratio) was employed to analyze the prognostic factors of OS in PDAC patients. Tumor budding and parasympathetic neurogenesis were included as dependent variables in the model. The results indicated that the presence of high-grade parasympathetic neurogenesis maintained its unfavorable impact on prognosis (P=0.009). Patients with high-grade parasympathetic neurogenesis had a 2.45-fold elevated risk of death after adjusting for the remaining features compared with patients with low-grade parasympathetic neurogenesis (*[Table 3](#T3){ref-type="table"}*).

###### 

Summary of important risk factors for overall survival in multivariate Cox regression analysis

  Factors                        n    β       S.E.    P\*     HR      95% CI
  ------------------------------ ---- ------- ------- ------- ------- -----------
  AJCC stage                                                          
  1                              11                           1.000   
  2-3                            48   1.136   0.441   0.010   3.115   1.31-7.40
  Tumor budding                                                       
  ≤17                            28                           1.000   
  \>17                           31   0.956   0.365   0.009   2.601   1.27-5.31
  Parasympathetic neurogenesis                                        
  ≤15                            20                           1.000   
  \>15                           39   0.898   0.343   0.009   2.454   1.25-4.81

Discussion
==========

The present study identified the association of high-grade parasympathetic neurogenesis with frequent occurrence of tumor budding and its role as an independent and highly unfavorable prognostic factor in PDAC, and deepens our understanding of the role of parasympathetic neurogenesis in PDAC in several aspects.

First, we found a significant progressive increase in the occurrence of parasympathetic neurogenesis from normal pancreas to PDAC. This implies that a progressive increase in parasympathetic neurogenesis may play a key role in pancreatic neoplastic transformation and that it is taking place even before invasion occurs. Similar findings were observed in previous studies, in which a high density of parasympathetic neurogenesis was found in high-risk prostate cancer ([@b1]) and gastric cancer ([@b17]).

Second, the role of the autonomic system in pancreatic cancer has been studied in recent years ([@b18], [@b19], [@b20]), but to our knowledge no studies have assessed the presence of parasympathetic neurogenesis in PDAC. Our findings might help to better stratify PDAC patients into prognostic subgroups and lead to better clinical decision making in terms of intraoperative or postoperative treatment modalities. According to the distribution of parasympathetic neurogenesis in our cases of PDAC, we propose two categories of parasympathetic neurogenesis: high grade and low grade. In the present study, high-grade parasympathetic neurogenesis was associated with aggressive clinicopathologic features of tumors such as the presence of tumor budding and early recurrence. Therefore, our data suggest that high-grade parasympathetic neurogenesis correlates with a more aggressive phenotype in PDAC. Moreover, parasympathetic neurogenesis was found to be the most important prognostic factor in PDAC patients, showing a higher prognostic ability than TNM stage in our series.

Third, prior studies have described a distinct phenomenon possibly analogous to angiogenesis ([@b1], [@b17]), that the tumor itself is infiltrated by a network of newly developed autonomic nerve projections that regulate cancer initiation and progression ([@b1], [@b17]). Studies of mouse models revealed that branches of the parasympathetic nervous system play an important role in tumor cell invasion, migration, and distant metastases through stromal Chrm1-mediated signals. In this context, parasympathetic neurogenesis can be considered not just as a simple distribution of parasympathetic nerves in the tumor, but through its association with invasion and metastasis can rather be regarded as a promoter of PDAC progression from local to systemic disease. Moreover, we observed that parasympathetic neurogenesis was strongly associated with a frequent occurrence of tumor budding. This finding probably reflects the fact that the rich parasympathetic neurogenesis of PDAC may actively participate in and promote the development of invasion and metastasis, although the contribution and role of parasympathetic neurogenesis in invasion and metastasis should be further confirmed.

Our study might be limited by the relatively small number of PDAC patients and the fact that all cases came from a single center. Nonetheless, our study benefits from complete clinicopathologic data with information on follow-up. Our findings need to be validated in larger series from multiple centers to find their proper place in everyday practice. These studies will allow us to gain further insight into the process of parasympathetic neurogenesis and provide us with a platform on which to build future *in vitro* and *in vivo* studies, with the aim of identifying new candidate molecules for future therapeutic interventions focusing on the destruction of parasympathetic neurogenesis.

Conclusions
===========

Our study provides the evidence that parasympathetic neurogenesis occurs frequently in PDAC and may be used as a parameter of tumor aggressiveness and as an indicator of unfavorable outcomes. Moreover, parasympathetic neurogenesis was strongly associated with the frequent occurrence of tumor budding, although the underlying mechanism is yet to be elucidated.
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